The category metabolic diseases as defined by the G-BA lists medicinal products for diseases such as diabetes mellitus, certain metabolic enzyme defects such as cystic fibrosis (CF) and hypercholesterolaemia. To date, the G-BA has assessed xx medicinal products in xx resolutions. In total, xx patient populations have been formed. Weighted by patient share in the respective resolution, a major additional benefit has been proved for xx% of the subpopulations, with a considerable additional benefit for XX%. A minor additional benefit has been identified for XX% of the subpopulations, whereas XX% have seen a non-quantifiable additional benefit.
The G-BA has seen no additional benefit proven for XX% of the subpopulations. This corresponds to xx% of the total xx million patients suitable for the assessed medicinal product but for whom no additional benefit was proven in relation to the comparative therapy.